-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Text|Pharmaceutical Mission Hills
On October 18, the Chinese drug clinical trial registration and information disclosure platform showed that Merck (MSD) and Seagen have launched a phase 3 clinical trial of tucatinib in China for the treatment of locally advanced or metastatic HER2-positive breast cancer
Screenshot source: Drug clinical trial registration and information disclosure platform
In breast cancer patients, many patients overexpress human epidermal growth factor receptor 2 (HER2), and HER2 protein promotes the growth of cancer cells, which seriously affects the treatment and prognosis of the patients
Tucatinib is an oral tyrosine kinase inhibitor developed by Seagen, which is highly specific for HER2, but has no obvious inhibitory effect on EGFR, which belongs to the human epidermal growth factor receptor family
In September 2020, Merck and Seagen reached a partnership to obtain the exclusive commercialization rights of tucatinib in Asia, the Middle East and Latin America, and other regions (outside the United States, Canada and Europe) for the treatment of HER2-positive cancers
The launch in China this time is a randomized, double-blind international multicenter phase 3 clinical trial (HER2CLIMB-02), which aims to evaluate the comparison of tucatinib or placebo combined with enmetrastuzumab in the treatment of unresectable locally advanced or Efficacy and safety of metastatic HER2-positive breast cancer
According to the information from the China Drug Clinical Trial Registration and Information Disclosure Platform, the trial is led by Professor Xu Binghe from the Cancer Hospital of the Chinese Academy of Medical Sciences as the main investigator.
It is worth mentioning that the phase 3 study of tucatinib, HER2CLIMB, has been evaluated by the American Society of Clinical Oncology (ASCO) as one of the 20 important clinical studies in the field of anti-cancer in 2020
references:
[1] China Drug Clinical Trial Registration and Information Disclosure Platform.
[3] Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations.
